Eco Animal Health reports that it has submitted a key Market Authorisation Application (MAA) to the European Medicines Agency (EMA), with supporting documentation, for its ECOVAXXIN®MS, Mycoplasma synoviae, vaccine. This represents an important step towards commercialisation for ECOVAXXIN®MS, one of nine major new vaccines under development. This is a process which we expect to be replicated and as CEO David Hallas notes, this “represents a pivotal moment for ECO”. Significantly, the Group continues to submit technical data to the US Department of Agriculture (USDA) for both ECOVAXXIN® Mycoplasma synoviae and ECOVAXXIN® Mycoplasma gallisepticum (MG), and expects to gain marketing approval in the US, subject to dossier review, at about the same time as in Europe.
Eco Animal Health: Equity Development
Mar 3, 2025Disclaimer & Declaration of Interest
The information, investment views and recommendations in this article are provided for general information purposes only. Nothing in this article should be construed as a solicitation to buy or sell any financial product relating to any companies under discussion or to engage in or refrain from doing so or engaging in any other transaction. Any opinions or comments are made to the best of the knowledge and belief of the writer but no responsibility is accepted for actions based on such opinions or comments. Vox Markets may receive payment from companies mentioned for enhanced profiling or publication presence. The writer may or may not hold investments in the companies under discussion.